MedTrace Logo

Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses

NCT05624320 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2024-04-09

No results posted yet for this study

Summary

AGN-190584 has gone through many clinical trials showing its safety and effectiveness in individuals from 40-55 years of age. There has been no published data on the use of this product in individuals corrected with contact lenses for distance vision. There are many other applications AGN-190584 could be used for and further studies will show the effectiveness for each.

Conditions

Interventions

DRUG

AGN-190584

miotic for treatment of presbyopia

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Gordon Schanzlin New Vision

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-05-30
Completion
2023-06-30
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05624320 on ClinicalTrials.gov